Chronic Disease
Recent clinical, regulatory, research and industry developments relating to this disease.
Neural Plasticity in Migraine Chronification.
Systematic low-grade chronic inflammation and intrinsic mechanisms in polycystic ovary syndrome.
Microplastics and human health: unveiling the gut microbiome disruption and chronic disease risks.
2024 ESC Guidelines for the management of chronic coronary syndromes.
Inflammation unites diverse acute and chronic diseases.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 regulatory approvals from EMA on record.
- Active recent publication activity, including 1 notable finding.
- 1 safety action from EMA issued.
- 1 clinical trial with recent milestones.
- 2 industry developments reported.
Research HighlightsViewHide
- 2025-10-01Revised European Society of Endocrinology Clinical Practice Guideline: Treatment of Chronic Hypoparathyroidism in Adults.Bollerslev J · 2025
- 2025-10-14From infectious diseases to chronic diseases: the paradigm shift of spatial epidemiology in disease prevention and control.Hu K · 2025
- 2025-12-22STAT3 Signaling Mediates Agomelatine Restoration of Prefrontal Cortex Synaptic Plasticity in Chronic Social Defeat Stress Mice.Lee CW · 2025
Clinical MilestonesViewHide
- 2025-12-01Efficacy of Alternate Dupilumab Schedule in Recurrent Chronic Rhinosinusitis With Nasal Polyposis PatientsPrimary completion
Industry & MarketViewHide
- 2026-07-08Bryan Johnson’s chronic disease is notoriously difficult to diagnoseIndustry · STAT News
- 2026-06-23STAT+: Cadence raises $100 million to automate chronic disease care with regulated AIIndustry · STAT News
Regulatory UpdatesViewHide
- 2026-05-29Approval — FurosemideBopediat is indicated in children from birth to less than 18 years of age for the treatment of oedema of cardiac or renal origin, oedema of hepatic origin, and hypertension in patients with chronic kidney disease.
- 2026-04-14Market withdrawal — LusutrombopagMulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures
- 2026-02-12Approval — DepemokimabAsthma Exdensur is indicated as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled despite high dose inhaled corticosteroids (ICS) plus another asthma controller (see section 5.1). Chronic rhinosinusitis with nasal polyps (CRSwNP) Exdensur is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
- 2025-08-22Approval — NintedanibNintedanib Viatris is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib Viatris is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. Nintedanib Viatris is indicated in children and adolescents from 6 to 17 years old for the treatment of clinically significant, progressive fibrosing interstitial lung diseases (ILDs). Nintedanib Viatris is indicated in adults, adolescents and children aged 6 years and older for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD).
- 2026-07-08IndustryBryan Johnson’s chronic disease is notoriously difficult to diagnoseIndustry · STAT News
- 2026-06-23IndustrySTAT+: Cadence raises $100 million to automate chronic disease care with regulated AIIndustry · STAT News
- 2026-05-29RegulatoryApproval — FurosemideBopediat is indicated in children from birth to less than 18 years of age for the treatment of oedema of cardiac or renal origin, oedema of hepatic origin, and hypertension in patients with chronic kidney disease.
- 2026-04-14RegulatoryMarket withdrawal — LusutrombopagMulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures
- 2026-02-12RegulatoryApproval — DepemokimabAsthma Exdensur is indicated as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled despite high dose inhaled corticosteroids (ICS) plus another asthma controller (see section 5.1). Chronic rhinosinusitis with nasal polyps (CRSwNP) Exdensur is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
- 2025-12-22ResearchSTAT3 Signaling Mediates Agomelatine Restoration of Prefrontal Cortex Synaptic Plasticity in Chronic Social Defeat Stress Mice.Lee CW · 2025
- 2025-12-01ClinicalEfficacy of Alternate Dupilumab Schedule in Recurrent Chronic Rhinosinusitis With Nasal Polyposis PatientsPrimary completion
- 2025-10-14ResearchFrom infectious diseases to chronic diseases: the paradigm shift of spatial epidemiology in disease prevention and control.Hu K · 2025
- 2025-10-01ResearchRevised European Society of Endocrinology Clinical Practice Guideline: Treatment of Chronic Hypoparathyroidism in Adults.Bollerslev J · 2025
- 2025-08-22RegulatoryApproval — NintedanibNintedanib Viatris is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib Viatris is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. Nintedanib Viatris is indicated in children and adolescents from 6 to 17 years old for the treatment of clinically significant, progressive fibrosing interstitial lung diseases (ILDs). Nintedanib Viatris is indicated in adults, adolescents and children aged 6 years and older for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD).
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Asthma Exdensur is indicated as add-on maintenance treatment for severe asthma with… (2026)
Approval — Bopediat is indicated in children from birth to less than 18 years of age for the treatme… (2026)
Approval — Nintedanib Viatris is indicated in adults for the treatment of idiopathic pulmonary fibro… (2025)
Approval — Psoriatic arthritis Apremilast Accord, alone or in combination with Disease Modifying Ant… (2024)
Approval — Allergic asthma Omlyclo is indicated in adults, adolescents and children (6 to <12 yea… (2024)
Approval — Type 2 diabetes mellitus Dapagliflozin Viatris is indicated in adults and children aged 1… (2023)
Approval — Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidn… (2023)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Inflammation3
- Antioxidants2
- Brain Injuries, Traumatic2
- Cardiology2
- Communicable Diseases2
- Cost of Illness2
- Epidemiologic Research Design2
- Heart Failure2
Leading journals6
- European heart journal7
- Frontiers in immunology7
- International journal of molecular sciences5
- The Journal of neuroscience : the official journal of the Society for Neuroscience4
- European journal of epidemiology3
- The New England journal of medicine3
Leading researchers8
- Jaarsma T3
- Stricker BH3
- Uitterlinden AG3
- Adamo M2
- Alomar SY2
- Alwasel SH2
- Bjermer L2
- Čelutkienė J2
Affiliations (unnormalised)6
- Aarhus University Hospital3
- Brigham and Women's Hospital3
- Ghent University Hospital3
- Medical University of Vienna3
- Amsterdam University Medical Centres2
- Charles University and Thomayer Hospital2
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Chronic disease refers to a class of illnesses that are long-lasting, may be permanent, and can leave residual disability or require prolonged supervision, observation, or care. In epidemiological use, it often includes conditions such as heart disease, stroke, cancer, and type 2 diabetes mellitus.
The grounding does not support a single cause or aetiology for chronic disease as a category. It is described as encompassing diseases with persistent or nonreversible pathological alteration rather than having one unified cause.
The literature grounding treats chronic disease as a broad category associated with shared biological processes rather than one mechanism. Reported mechanisms across chronic diseases include oxidative stress, chronic inflammation and cytokine signaling, altered signal transduction, aging-related changes, wound healing and tissue remodeling, neuronal plasticity, and matrix metalloproteinase-mediated extracellular matrix turnover.
Supported risk factors in the grounding are broad and mechanism-linked rather than disease-specific. These include psychological stress, diet, lifestyle factors, aging, cigarette smoking, pollution, radiation, certain drugs, and prior child maltreatment as a long-term risk factor for later mental and physical health outcomes.
The grounding does not support a single standard treatment for chronic disease as a category. It indicates that management is disease-specific and may involve targeted therapies in some chronic inflammatory diseases, along with rehabilitation, long-term supervision, and care.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.